Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 10/2012

01-10-2012 | Educational Series – Red Series*

Surveillance of resected non-small cell lung cancer

Authors: A. López-González, P. Ibeas Millán, B. Cantos, M. Provencio

Published in: Clinical and Translational Oncology | Issue 10/2012

Login to get access

Abstract

Lung cancer is the most common cancer in the world. 15 % of all patients with lung cancer are diagnosed at an early stage, and surgery is the treatment of choice for them. 40 % of all patients survive more than 5 years after surgery, and most of them die as a result of systemic disease. Half of all recurrences are diagnosed within the first 24 months after curative treatment, and 90 % in the first 5 years. Despite this, it is not standardized who should do the monitoring, what additional tests are needed and how often should they be performed. We present here a review on the various recommendations in clinical guidelines.
Literature
1.
Non-small Cell Lung Cancer Collaborative Group (1995) Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 311:899–909CrossRef
2.
Mountain CF (1986) A new international staging system for lung cancer. Chest 89:225–233
3.
Harpole DH (1995) A prognostic model of recurrence and death in stage I non-small cell lung utilizing presentation histopathology and oncoprotein expression. Cancer Res 55:51–56PubMed
4.
Pairolero PC (1984) Postsurgical stage I bronchogenic carcinoma: morbid implications of recurrent disease. Ann Thorac Surg 38:331–336PubMedCrossRef
5.
Virgo KS (1996) Cost of patient follow-up after potentially curative lung cancer treatment. J Thorac Cardiovasc Surg 112:356–363PubMedCrossRef
6.
Shields TW (1978) Long-term survivors after resection of lung carcinoma. J Thorac Cardiovasc Surg 76:439–445PubMed
7.
Frank A et al (1995) Decision logic for retreatment of asymptomatic lung cancer recurrence based on positron emission tomography findings. Int J Radiat Oncol Biol Phys 32(5):1495–1512PubMedCrossRef
8.
Di Maio M (2010) Clinical assessment of patients with advanced non-small-cell lung cancer eligible for second-line chemotherapy: a prognostic score from individual data of nine randomised trials. Eur J Cancer 46(4):735–743PubMedCrossRef
9.
10.
Lamont JP (2002) Systematic postoperative radiologic follow-up in patients with non-small cell lung cancer for detecting second primary lung cancer in stage IA. Arch Surg 137(8):935–938PubMedCrossRef
11.
Gilbert S et al (2000) Who should follow up lung cancer patients after operation? Ann Thorac Surg 69:1696–1700PubMedCrossRef
12.
Varela G (1998) Follow-up of patients with non-small-cell pulmonary cancer undergoing complete resection. Should surgeons be in charge? Arc Bronconeumol 34(1):14–6
13.
Moore S et al (2002) Nurse led follow up and conventional medical follow up in management of patients with lung cancer: randomised trial. BMJ 325:1145–1152PubMedCrossRef
14.
Naunheim KS (1995) Clinical surveillance testing after lung cancer operations. Ann Thorac Surg 60:1612PubMedCrossRef
15.
Virgo KL (1995) Post-treatment management options for patients with lung cancer. Ann Surg 222:700–710PubMedCrossRef
16.
Walsh GL (1995) Is follow-up of lung cancer patients after resection medically indicated and cost-effective? Ann Thorac Surg 60(6):1563–1570PubMedCrossRef
17.
18.
Egermann U (2002) Regular follow-up after curative resection of non-small cell lung cancer: a real benefit for patients. Eur Respir J 19(3):464–468PubMedCrossRef
19.
Westeel V et al (2007) Protocole IFCT-0302: essai randomise de deux schémas de surveillance dans les cancers bronchiques non à petites cellules complètement réséqués. Rev Mal Respir 24:645–652PubMedCrossRef
20.
Tufman A et al (2010) Biological markers in lung cancer: a clinician’s perspective. Cancer Biomark 6(3–4):123–135PubMed
21.
Ghosal R et al (2009) A review of novel biological tools used in screening for the early detection of lung cancer. Postgrad Med J 85(1005):358–363PubMedCrossRef
22.
Cho S, Lee EG (2010) A follow-up of integrated positron emission tomography/computed tomography after curative resection of non-small-cell lung cancer in asymptomatic patients. J Thorac Cardiovasc Surg 139(6):1447–1451PubMedCrossRef
23.
Isobe K et al (2009) Usefulness of fluoro-2-deoxyglucose positron emission tomography for investigating unexplained rising carcinoembryonic antigen levels that occur during the postoperative surveillance of lung cancer patients. Int J Clin Oncol 14(6):497–501PubMedCrossRef
24.
Kanzaki R et al (2010) Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients. Interact Cardiovasc Thorac Surg 10(6):1009–1014PubMedCrossRef
25.
Rosell R (2009) Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 361:958–967PubMedCrossRef
26.
Carlson JJ (2009) Epidermal growth factor receptor genomic variation in NSCLC patients receiving tyrosine kinase inhibitor therapy: a systematic review and meta-analysis. J Cancer Res Clin Oncol 135(11):1483–1493PubMedCrossRef
27.
Dahabreh IJ (2010) Somatic EGFR mutation and gene copy gain as predictive biomarkers for response to tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res 16(1):291–303PubMedCrossRef
28.
Massarelli E (2007) KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clin Cancer Res 13(10):2890–2896PubMedCrossRef
29.
Linardou H (2008) Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol 9(10):962–972PubMedCrossRef
30.
Takeda M (2010) De novo resistance to epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR mutation-positive patients with non-small cell lung cancer. J Thorac Oncol 5(3):399–400PubMedCrossRef
31.
Carpagnano GE et al (2008) New biomolecular methodologies in diagnosis of lung cancer. Recenti Prog Med 99(9):417–421PubMed
32.
Han W et al (2009) Gene promoter methylation assayed in exhaled breath, with differences in smokers and lung cancer patients. Respir Res 25(10):86CrossRef
33.
Belinsky SA et al (2002) Aberrant promoter methylation in bronchial epithelium and sputum from current and former smokers. Cancer Res 62(8):2370–2377PubMed
34.
35.
Carpagnano GE et al (2010) Cigarette smoke and increased COX-2 and surviving levels in exhaled breath condensate of lung cancer patients: how hot is the link? Lung Cancer 67(1):108–113PubMedCrossRef
36.
Hsu HS et al (2007) Multiple genetic and epigenetic biomarkers for lung cancer detection in cytologically negative sputum and a nested case-control study for risk assessment. J Pathol 213(4):412–419PubMedCrossRef
37.
Gomperts BN et al (2010) Lung cancer biomarkers: FISHing in the sputum for risk assessment and early detection. Cancer Prev Res (Phila Pa) 3(4):420–423CrossRef
38.
Varella-Garcia M et al (2010) The detection of chromosomal aneusomy by fluorescence in situ hybridation in sputum predicts lung cancer incidence. Cancer Prev Res (Phila Pa) 3(4):447–453CrossRef
39.
Wang H et al (2010) Expression of Hsp27 and Hsp70 in lymphocytes and plasma in healthy workers and coal miners with lung cancer. J Huazhong Univ Sci Technolog Med Sci 30(4):415–420PubMedCrossRef
40.
Gube M et al (2011) Performance of biomarkers SMRP, CA125, and CYFRA 21-1 as potential tumor markers for malignant mesothelioma and lung cancer in a cohort of workers formerly exposed to asbestos. Arch Toxicol 85(3):185–192
41.
Hsu HS et al (2007) Characterization of a multiple epigenetic marker panel for lung cancer detection and risk assessment in plasma. Cancer 110(9):2019–2026PubMedCrossRef
42.
Gao K (2009) Systemic disease-induced salivary biomarker profiles in mouse models of melanoma and non-small cell lung cancer. PLoS One 4(6):e5875PubMedCrossRef
43.
Rubins J et al (2007) Follow-up and surveillance of the lung cancer patient following curative intent therapy: ACCP evidence-based clinical practice guideline (2nd edition). Chest 132(3 Suppl):355S–367SPubMedCrossRef
Metadata
Title
Surveillance of resected non-small cell lung cancer
Authors
A. López-González
P. Ibeas Millán
B. Cantos
M. Provencio
Publication date
01-10-2012
Publisher
Springer Milan
Published in
Clinical and Translational Oncology / Issue 10/2012
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-012-0841-z

Other articles of this Issue 10/2012

Clinical and Translational Oncology 10/2012 Go to the issue

Special Article

Guidelines for biomarker testing in colorectal carcinoma (CRC): a national consensus of the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM)

Research Article

Epidemiology and prevalence of oropharyngeal candidiasis in Spanish patients with head and neck tumors undergoing radiotherapy treatment alone or in combination with chemotherapy

Research Article

Outcomes and prognostic factors of conformal radiotherapy versus intensity-modulated radiotherapy for nasopharyngeal carcinoma

Research Article

Intensity modulated radiotherapy (IMRT) with simultaneous integrated boost (SIB) in a patient with left breast cancer and pectus excavatum

Editorial

Cost-effectiveness, cancer burden and financial crisis: a perfect storm

Research Article

The SGBS cell strain as a model for the in vitro study of obesity and cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits